Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

GDUFA II: ANDAs, Not Facilities Will Govern Revenue

Executive Summary

Since applications comprise most of the workload, they will be the focus in the next generic drug user fee cycle.


Related Content

ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal
ANDA Approvals, Submissions Decline With New Review Goal Coming
GDUFA Negotiations Shift To 'Tiered' Fee Models
ANDA User Fees Offer Sponsor Relief, But More Facility Pain
Will PDUFA VI Fee Structure Changes Slow Revenue Growth?
FDA's Generic Drug Workload, Productivity Beating Budget Estimates
ANDA Reviews: First-Cycle Desired, But Two-Cycles OK?
GDUFA II: Facility Fees Might Be Deferred Until ANDA Approval
Generic User Fees Need Small Business Waiver, Firms Say; Congress May Agree
Generic Facility Fee Unlikely To Be Charged Until A Few Months After GDUFA Implementation